C4 Therapeutics Inc (CCCC)

$2.92 +0.09 (3.18%)
Market Cap 276.15M
Revenue (ttm) 35.95M
Net Income (ttm) -104.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -292.04%
Debt to Equity Ratio 0.00
Volume 4,847,400
Avg Vol 3,055,970
Day's Range N/A - N/A
Shares Out 97.58M
Stochastic %K 59%
Beta 2.85
Analysts Strong Sell
Price Target $11.57

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 231 0700
Address:
490 Arsenal Way, Suite120, Watertown, United States
vu_jade
vu_jade May. 2 at 3:24 PM
$CCCC Volume ramping … liking the quick turnaround
0 · Reply
2tacos_plis
2tacos_plis May. 1 at 8:03 PM
$CCCC 😂This bogus company that masquerades as a therapeutics Co. Also has a bogus investors strategy (scam). Their hedge funds at amateur hour couldn’t be more obvious in shorting the stock. Bet against your company like Pete Rose. And where did that get him!
0 · Reply
Andysss
Andysss May. 1 at 6:32 PM
$CCCC small squeeze comming
1 · Reply
vu_jade
vu_jade May. 1 at 4:51 PM
$CCCC Great looking chart
0 · Reply
BioPM1989
BioPM1989 May. 1 at 11:16 AM
$CCCC <Vibetrade> I’m dancing in the mirror and singing in the shower </Vibetrade>
1 · Reply
BioKut
BioKut Apr. 30 at 11:49 PM
$CCCC
0 · Reply
vu_jade
vu_jade Apr. 30 at 7:59 PM
$CCCC like in golf … it’s not how it’s how many!
0 · Reply
zawojak
zawojak Apr. 30 at 7:53 PM
$CCCC yeah ! Ghooo Ghooo my precious💎
0 · Reply
JuggernautRaider
JuggernautRaider Apr. 30 at 7:36 PM
$CCCC 💪 💎 👊
0 · Reply
vu_jade
vu_jade Apr. 30 at 7:09 PM
$CCCC long 40k … let’s go
1 · Reply
Latest News on CCCC
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

Apr 9, 2026, 9:34 AM EDT - 23 days ago

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Apr 9, 2026, 6:59 AM EDT - 23 days ago

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

Mar 25, 2026, 7:00 AM EDT - 5 weeks ago

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 8:00 AM EDT - 7 weeks ago

C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 9, 2026, 4:01 PM EDT - 7 weeks ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:50 AM EST - 2 months ago

C4 Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 26, 2026, 7:00 AM EST - 2 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in Upcoming March Conferences

Feb 23, 2026, 7:10 AM EST - 2 months ago

C4 Therapeutics to Participate in Upcoming March Conferences

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Feb 23, 2026, 7:00 AM EST - 2 months ago

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 11:30 AM EST - 2 months ago

C4 Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

Jan 14, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:25 PM EST - 5 months ago

C4 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 5 months ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

C4 Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 8:30 AM EST - 6 months ago

C4 Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:00 AM EST - 6 months ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

Oct 16, 2025, 7:08 AM EDT - 7 months ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Oct 1, 2025, 7:00 AM EDT - 7 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Transcript: Status Update

Sep 20, 2025, 3:00 PM EDT - 7 months ago

C4 Therapeutics Transcript: Status Update

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 20, 2025, 11:00 AM EDT - 8 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 4, 2025, 7:00 AM EDT - 8 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Sep 3, 2025, 7:00 AM EDT - 8 months ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:00 AM EDT - 9 months ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 9:10 AM EST - 1 year ago

C4 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

C4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

C4 Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

C4 Therapeutics Transcript: Status Update

Dec 8, 2024, 5:00 PM EST - 1 year ago

C4 Therapeutics Transcript: Status Update

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 3:00 AM EST - 1 year ago

C4 Therapeutics Transcript: Jefferies London Healthcare Conference 2024

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

C4 Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 8:35 AM EDT - 1 year ago

C4 Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

C4 Therapeutics Transcript: Study Update

Sep 13, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Transcript: Study Update

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 8:45 AM EDT - 1 year ago

C4 Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

C4 Therapeutics Transcript: UBS Targeted Protein Degradation Day 2024

Jul 15, 2024, 12:00 PM EDT - 1 year ago

C4 Therapeutics Transcript: UBS Targeted Protein Degradation Day 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Jun 10, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 16, 2024, 10:30 AM EDT - 2 years ago

C4 Therapeutics Transcript: Stifel Virtual Targeted Oncology Days Conference

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 9, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Apr 8, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Mar 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 11, 2024, 12:00 PM EST - 2 years ago

C4 Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Transcript: Study Update

Dec 12, 2023, 4:30 PM EST - 2 years ago

C4 Therapeutics Transcript: Study Update

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

C4 Therapeutics Announces Chief Financial Officer Succession

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 8, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 15, 2023, 1:58 AM EDT - 3 years ago

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Transcript: 41st Annual J.P. Morgan Healthcare Conference

Jan 9, 2023, 1:30 PM EST - 3 years ago

C4 Therapeutics Transcript: 41st Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Transcript: Credit Suisse 31st Annual Healthcare Conference

Nov 8, 2022, 5:00 PM EST - 3 years ago

C4 Therapeutics Transcript: Credit Suisse 31st Annual Healthcare Conference

C4 Therapeutics Transcript: BofA Securities Precision Oncology Conference

Oct 3, 2022, 9:50 AM EDT - 3 years ago

C4 Therapeutics Transcript: BofA Securities Precision Oncology Conference

C4 Therapeutics Transcript: UBS Global Healthcare Virtual Conference 2021

May 26, 2021, 8:00 AM EDT - 5 years ago

C4 Therapeutics Transcript: UBS Global Healthcare Virtual Conference 2021

vu_jade
vu_jade May. 2 at 3:24 PM
$CCCC Volume ramping … liking the quick turnaround
0 · Reply
2tacos_plis
2tacos_plis May. 1 at 8:03 PM
$CCCC 😂This bogus company that masquerades as a therapeutics Co. Also has a bogus investors strategy (scam). Their hedge funds at amateur hour couldn’t be more obvious in shorting the stock. Bet against your company like Pete Rose. And where did that get him!
0 · Reply
Andysss
Andysss May. 1 at 6:32 PM
$CCCC small squeeze comming
1 · Reply
vu_jade
vu_jade May. 1 at 4:51 PM
$CCCC Great looking chart
0 · Reply
BioPM1989
BioPM1989 May. 1 at 11:16 AM
$CCCC <Vibetrade> I’m dancing in the mirror and singing in the shower </Vibetrade>
1 · Reply
BioKut
BioKut Apr. 30 at 11:49 PM
$CCCC
0 · Reply
vu_jade
vu_jade Apr. 30 at 7:59 PM
$CCCC like in golf … it’s not how it’s how many!
0 · Reply
zawojak
zawojak Apr. 30 at 7:53 PM
$CCCC yeah ! Ghooo Ghooo my precious💎
0 · Reply
JuggernautRaider
JuggernautRaider Apr. 30 at 7:36 PM
$CCCC 💪 💎 👊
0 · Reply
vu_jade
vu_jade Apr. 30 at 7:09 PM
$CCCC long 40k … let’s go
1 · Reply
vu_jade
vu_jade Apr. 30 at 6:45 PM
$CCCC anyone else buy yesterdays shake out? Great job!
0 · Reply
vu_jade
vu_jade Apr. 30 at 3:22 PM
$CCCC set up is just right!
0 · Reply
vu_jade
vu_jade Apr. 30 at 12:06 PM
$CCCC light volume shakeout .. inverse head & shoulders look. Catalysts ahead GiddyUp
0 · Reply
vu_jade
vu_jade Apr. 29 at 6:23 PM
$CCCC Roche deal gives cash and credibility .. this is a transformative year .. shake out today Volume weak .. hitting 200 DMA Peace
0 · Reply
vu_jade
vu_jade Apr. 29 at 6:09 PM
$CCCC $2.54 $2.53 $2.52 Gifts
0 · Reply
LabPsycho
LabPsycho Apr. 29 at 2:43 PM
$CCCC @BioPM1989 Well, so far your Mom is correct. The ERAS situation not helping degraders. Esp. if connected to China R&D in any way?
1 · Reply
vu_jade
vu_jade Apr. 28 at 8:12 PM
$CCCC even better price than last week
0 · Reply
BioPM1989
BioPM1989 Apr. 28 at 4:56 PM
$CCCC Bearish chart formation. (Mom says)
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 27 at 9:18 PM
$CCCC Current Stock Price: $2.85 Contracts to trade: $3.0 CCCC May 15 2026 Call Entry: $0.10 Exit: $0.20 ROI: 98% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
vu_jade
vu_jade Apr. 27 at 1:44 PM
$CCCC we buy dips We sell rips
0 · Reply
zawojak
zawojak Apr. 27 at 7:09 AM
$CCCC week with opportunity to average down I suppose
0 · Reply
BioPM1989
BioPM1989 Apr. 25 at 1:58 PM
$CCCC Mom made me pancakes. She also told me shes short C4. Second best trader I know…
0 · Reply